These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15229296)

  • 1. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
    Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB
    Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
    Holzer AK; Katano K; Klomp LW; Howell SB
    Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
    Holzer AK; Manorek GH; Howell SB
    Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The internalization and degradation of human copper transporter 1 following cisplatin exposure.
    Holzer AK; Howell SB
    Cancer Res; 2006 Nov; 66(22):10944-52. PubMed ID: 17108132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1).
    Du X; Wang X; Li H; Sun H
    Metallomics; 2012 Jul; 4(7):679-85. PubMed ID: 22552365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
    Kalayda GV; Wagner CH; Jaehde U
    J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
    Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
    Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
    Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
    Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U
    Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
    Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
    Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression, localisation and hormone regulation of the human copper transporter hCTR1 in placenta and choriocarcinoma Jeg-3 cells.
    Hardman B; Manuelpillai U; Wallace EM; Monty JF; Kramer DR; Kuo YM; Mercer JF; Ackland ML
    Placenta; 2006; 27(9-10):968-77. PubMed ID: 16356544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the human copper influx transporter 1 in normal and malignant human tissues.
    Holzer AK; Varki NM; Le QT; Gibson MA; Naredi P; Howell SB
    J Histochem Cytochem; 2006 Sep; 54(9):1041-9. PubMed ID: 16709730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.
    Hamelers IH; Staffhorst RW; Voortman J; de Kruijff B; Reedijk J; van Bergen en Henegouwen PM; de Kroon AI
    Clin Cancer Res; 2009 Feb; 15(4):1259-68. PubMed ID: 19228729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
    Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
    Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
    Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
    Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
    J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.